SUZHOU, China, Dec. 17, 2023 /PRNewswire/ -- Recently, GeneQuantum Healthcare (GQ), a global leader in ADC new drug development focused on innovative bioconjugation technologies, and BioMap, a global leader in life science AI Foundation protein-centric Large Language Models, announced that they have entered into a strategic collaboration agreement to co-develop FIC/BIC ADC therapeutics for multiple targets.

中国苏州，2023年12月17日/PRNewswire/--最近，全球ADC新药开发领导者GeneQuantum Healthcare（GQ）专注于创新的生物缀合技术，以及全球生命科学AI基金会以蛋白质为中心的大型语言模型领导者BioMap，宣布他们已签署战略合作协议，共同开发针对多个目标的FIC/BIC ADC治疗剂。

The partnership will combine GQ's proprietary enzymatic site-specific conjugation technology platforms (iLDC® and iGDC®), linker-payload platform, with BioMap's proprietary trillion-parameter life science AI Foundation Large Language Model xTrimo and AI protein generation platform AIGP, to create novel ADCs addressing high unmet medical needs..

该合作伙伴关系将结合GQ专有的酶促位点特异性结合技术平台（iLDC®和iGDC®），链接器有效载荷平台，以及BioMap专有的万亿参数生命科学AI基金会大型语言模型xTrimo和AI蛋白质生成平台AIGP，创建新型ADC，以满足高度未满足的医疗需求。。

Under the terms of the collaboration agreement, GQ and BioMap will integrate resources to discover and develop novel ADC therapies. This includes utilizing BioMap's innovative target recommendation platform and high performance antibody design platform AIGP under the xTrimo, the enzymatic site-specific conjugation technology platforms iLDC® and iGDC®, the linker-payload technology platform, and leverage the expertise in high-quality data mining and utilization, cross-model data integration and analysis, target discovery, antibody design, ADC conjugation preparation, ADC drug evaluation, differentiated indication development, and business development collaborations.

根据合作协议的条款，GQ和BioMap将整合资源以发现和开发新型ADC疗法。这包括利用xTrimo下的BioMap创新目标推荐平台和高性能抗体设计平台AIGP，酶促位点特异性结合技术平台iLDC®和iGDC®，链接器有效载荷技术平台，并利用高质量数据挖掘和利用，跨模型数据集成和分析，目标发现，抗体设计，ADC缀合制备，ADC药物评估，差异化适应症开发和业务开发合作。

By leveraging each partner's capabilities, the collaboration aims to create highly competitive and innovative ADC drugs to address global unmet clinical needs..

通过利用每个合作伙伴的能力，该合作旨在创造极具竞争力和创新性的ADC药物，以满足全球未满足的临床需求。。

Dr. Gang Qin, Founder and Chairman of GQ, said, 'GQ and BioMap share a similar vision and commitment to disruptive innovation that can improve the quality of patients' lives. We both value open collaboration, innovation empowerment, and ecosystem construction. By serving as a central hub for an advanced conjugation solution, we bring together exceptional resources from all partners to foster collaborative synergy, which will significantly enhance the R&D efficiency of innovative ADC drugs, reduce development costs, and cultivate the development of high-quality next-generation ADC therapeutics.

GQ创始人兼董事长秦刚博士表示，“GQ和BioMap对可以改善患者生活质量的颠覆性创新有着相似的愿景和承诺。我们都重视开放合作、创新授权和生态系统建设。通过作为先进结合解决方案的中心枢纽，我们汇集了所有合作伙伴的特殊资源，以促进协同增效，这将大大提高创新ADC药物的研发效率，降低开发成本，并促进高质量下一代ADC治疗剂的开发。

The goal is to better address the growing medical needs and bring better treatment options to patients worldwide. With the established collaboration with BioMap, our global bioconjugation ecosystem welcomes another important partner. We look forward to fully integrating GQ' expertise and experience in ADC drug development with BioMap's profound understanding of life sciences foundational large models, high-performance computing, and AI.

目标是更好地满足日益增长的医疗需求，并为全球患者带来更好的治疗选择。通过与BioMap建立的合作关系，我们的全球生物共轭生态系统欢迎另一个重要合作伙伴。我们期待着将GQ在ADC药物开发方面的专业知识和经验与BioMap对生命科学基础大型模型，高性能计算和AI的深刻理解充分结合起来。

Our goal is to accelerate the development of a series of breakthrough ADC therapeutics, thereby creating a new paradigm in the global ADC drug development landscape.'.

我们的目标是加速开发一系列突破性的ADC疗法，从而在全球ADC药物开发领域创造新的范例。”。

Ms. Vicky Qu, Senior VP of BioMap, said, 'Target discovery is another broad market outside of the protein drug design. BioMap has built its own task model system around immune cell activation, disease-specific target recommendation, and drug combination recommendation, and has also achieved several related collaborations recently.

BioMap高级副总裁Vicky Qu女士说，“靶标发现是蛋白质药物设计之外的另一个广阔市场。BioMap围绕免疫细胞激活，疾病特异性靶标推荐和药物组合推荐建立了自己的任务模型系统，并且最近还实现了一些相关的合作。

We are honored to collaborate with GQ on the development of next generation ADC drugs. Based on the robust Foundation Model and the extensive accumulation of life science data at BioMap, we recommend novel targets and target combinations for ADC drugs, and rapidly design high-performance antibody components through the BioMap AIGP platform.

我们很荣幸与GQ合作开发下一代ADC药物。基于BioMap强大的基础模型和生命科学数据的广泛积累，我们推荐ADC药物的新型靶标和靶标组合，并通过BioMap AIGP平台快速设计高性能抗体成分。

Our goal is to improve the safety and efficacy of ADC drugs by making more precise disease selections. The Foundation Model for life sciences has even more potential, and we also welcome more biocomputing developers to experience BioMap's platform. Together, we can define diverse demands for life science R&D scenarios and construct dedicated task models, bringing generative capabilities to cutting-edge discovery challenges in the life sciences industry, and achieving breakthrough results in more fields.'.

我们的目标是通过更精确的疾病选择来提高ADC药物的安全性和有效性。生命科学的基础模型具有更大的潜力，我们也欢迎更多的生物计算开发人员体验BioMap平台。总之，我们可以定义生命科学研发场景的不同需求，构建专用任务模型，为生命科学行业的前沿发现挑战带来生成能力，并在更多领域取得突破性成果。”。

About GeneQuantum Healthcare

关于GeneQuantum Healthcare

GeneQuantum, headquartered in China, is a global leader in the ADC field, distinguished for its advancement of enzymatic site-specific conjugation technologies. Our pioneering technologies, iLDC and iGDC, serve as the foundation of our comprehensive ADC drug development platform, spanning from the initial design to seamless commercial production..

GeneQuantum总部位于中国，是ADC领域的全球领导者，以其酶促位点特异性结合技术的进步而闻名。我们的领先技术iLDC和iGDC是我们全面的ADC药物开发平台的基础，从最初的设计到无缝的商业生产。。

For more information about GeneQuantum, please visit: www.genequantum.com

有关GeneQuantum的更多信息，请访问：www.GeneQuantum.com

About BioMap

关于BioMap

Founded in 2020 by Robin Li and Wei Liu, BioMap is a disruptive life science AI company responsible for building xTrimo, the first and largest protein-centric large language model platform. Their technology allows scientists to model life more accurately, from proteins to a system level, and extract novel insights and predictions from limited data.

BioMap由Robin Li和Wei Liu于2020年成立，是一家颠覆性的生命科学人工智能公司，负责构建xTrimo，这是第一个也是最大的以蛋白质为中心的大型语言模型平台。他们的技术使科学家能够更准确地模拟生命，从蛋白质到系统水平，并从有限的数据中提取新的见解和预测。

Supported by an international, cross-functional team of over 300 experts, BioMap is solving critical, protein-related drug development problems and charting a course to radically improve patients' lives..

在由300多名专家组成的国际跨职能团队的支持下，BioMap正在解决与蛋白质相关的关键药物开发问题，并制定出从根本上改善患者生活的路线。。

For more information about BioMap, please visit: www.biomap.com

有关BioMap的更多信息，请访问：www.BioMap.com

SOURCE GeneQuantum Healthcare

来源GeneQuantum Healthcare